Capricor Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
BLA for Deramiocel accepted by FDA with PDUFA date set for August 2026, following strong HOPE-3 trial results showing efficacy in DMD. Cash position is robust at $318M, with manufacturing expansion and commercial launch preparations underway.
-
The phase III HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy met its primary and key secondary endpoints, showing significant slowing of upper limb and cardiac deterioration with a strong safety profile. Regulatory submission is planned, and the therapy is positioned for use alongside other treatments.
-
Positive phase III data for deramiocel in DMD showed significant improvements in both cardiac and skeletal muscle function, supporting a broad label and full FDA approval. Commercial manufacturing is ready, partnerships are in place, and expansion into new indications and exosome-based therapies is planned.
-
HOPE-3 phase III data for deramiocel in Duchenne muscular dystrophy showed significant improvements in both skeletal and cardiac function, meeting all primary and secondary endpoints with strong safety and tolerability. The results address FDA concerns, support broad patient use, and position the therapy for regulatory approval and commercial launch.
-
Top-line HOPE-3 data for Deramiocel in Duchenne muscular dystrophy is imminent, with FDA review and potential approval targeted for 2026. Cash reserves of $98.6 million support operations into late 2026, and a strong safety profile and commercial readiness position the company for launch if approved.
-
FDA will review HOPE-3 trial data for DMD, allowing both skeletal and cardiac endpoints for potential dual labeling. Top-line results are expected mid-November, with strong safety and efficacy powering, and financial resources support launch readiness.
-
Q2 2025 saw no revenue and a higher net loss as the company awaits FDA feedback on deramiocel for DMD cardiomyopathy. Cash reserves remain strong, supporting operations into late 2026, while the exosomes platform advances with a Phase I COVID-19 vaccine trial.
-
FDA issued a Complete Response Letter for the BLA of Deramiocel, requesting more clinical data and citing statistical analysis concerns. The ongoing HOPE-3 Phase 3 trial is expected to address these issues, with data anticipated in Q3 2025. Regulatory engagement and stakeholder support remain strong.
-
BLA for deramiocel in DMD cardiomyopathy is progressing, with strong clinical data and preparations for commercial launch underway. Cash runway extends into 2027, and FDA approval could bring over $200 million in non-dilutive funding.
-
Deramiocel, an allogeneic cell therapy for Duchenne cardiomyopathy, is advancing toward FDA approval with a PDUFA date of August 31, 2025. Clinical trials show significant slowing of disease progression and a strong safety profile, with commercial launch and revenue generation expected by year-end.
-
The session highlighted the progress of an allogeneic cell therapy for DMD cardiomyopathy, with strong clinical data, a pending BLA, and robust commercial partnerships. Expansion into new indications and exosome-based therapeutics is planned, supported by solid financials.
Fiscal Year 2024
-
BLA for deramyocel in DMD cardiomyopathy accepted for FDA priority review, with strong efficacy and safety data supporting potential approval by August 2025. Commercial launch preparations and manufacturing expansion are underway, backed by a robust cash position and positive payer feedback.
-
Deramiocel demonstrated strong efficacy and durability in Duchenne cardiomyopathy, with a BLA filing planned by year-end and potential US approval in late 2025. Manufacturing and commercial partnerships are in place, and the exosome platform is advancing toward new clinical programs.
-
BLA submission for deramiocel in DMD cardiomyopathy is on track, with strong clinical data and FDA collaboration supporting a de-risked path to potential approval in H2 2025. Financials show a strengthened cash position and ongoing commercial, manufacturing, and pipeline expansion efforts.
-
A BLA for Deramiocel in DMD cardiomyopathy is being submitted based on robust HOPE-2 and open label extension data, showing significant cardiac benefits and safety. The therapy targets all DMD patients, with global expansion and rapid adoption expected.
-
Strong clinical and regulatory progress for deramiocel in DMD, with rolling BLA submission imminent and significant partnership and milestone opportunities ahead. Financials show increased R&D investment and a cash runway into Q1 2025, with ex-U.S. deals targeted by year-end.